步長製藥(603858.SH):非公開發行公司債券掛牌轉讓無異議函到期
格隆匯 3 月 22日丨步長製藥(603858.SH)公佈,公司於2020年3月24日收到上海證券交易所(“上交所”)出具的《關於對山東步長製藥股份有限公司非公開發行公司債券掛牌轉讓無異議的函》(上證函[2020]557號)。根據《無異議函》,上交所對公司面向合格投資者非公開發行總額不超過6.5億元的公司債券無異議,該《無異議函》自出具之日起12個月內有效。
取得上述無異議函後,公司與中介機構積極有序推動本次非公開發行公司債券的各項工作,但鑑於資本市場環境、融資成本等多方面發生變化,為保證公司及廣大股東利益,公司未在無異議函有效期內(自2020年3月24日至2021年3月23日)實施此次非公開發行公司債券,上交所出具的無異議函到期自動失效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.